QMDT.US Quick-Med Technologies Inc
- Market cap
- USD 18.7K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2013.
Is QMDT.US undervalued?
Graham numberThe Graham number of Quick-Med Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Quick-Med Technologies Inc fundamental analysis
No fundamental analysis for Quick-Med Technologies Inc yet.
Quick-Med Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Quick-Med Technologies Inc
Quick-Med Technologies, Inc. focuses on sustainable antimicrobial technologies. It provides treatment optimization, laboratory prototyping to factory scale-up, domestic and international regulatory guidance, microbiological efficacy testing including viruses, patent expertise, technology evaluations, antimicrobials market evaluations, and scientific invention and original research products. The company's core technologies include Nimbus, a non-leaching antimicrobial wound dr…
Full company profileQuick-Med Technologies Inc financial statements
Quick-Med Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 48.0K | 182K | 1.23M | 1.95M | 1.36M | 1.00M | 994K | 1.04M | 997K | 928K |
| Gross Profit | 48.0K | 154K | 1.04M | 1.67M | 1.30M | 745K | 709K | 692K | 672K | 648K |
| Operating Income | -2.28M | -1.85M | -1.64M | -1.58M | -2.22M | -1.77M | -2.08M | -2.05M | -1.24M | -376K |
| EBITDA | -2.23M | -1.81M | -1.59M | -1.52M | -2.15M | -1.69M | -2.01M | -1.79M | -1.17M | -230K |
| Net Income | -2.37M | -1.93M | -1.70M | -1.51M | -2.39M | -2.02M | -3.55M | -2.30M | -1.69M | -713K |
| EPS | -0.14 | -0.08 | -0.06 | -0.05 | -0.08 | -0.07 | -0.11 | -0.07 | -0.05 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 386K | 1.23M | 526K | 965K | 909K | 493K | 1.35M | 1.64M | 612K | 723K |
| Total Liabilities | 2.55M | 1.58M | 1.81M | 2.98M | 4.51M | 5.46M | 7.64M | 8.09M | 8.68M | 9.78M |
| Shareholders' Equity | -2.17M | -352K | -1.28M | -2.01M | -3.60M | -4.96M | -6.29M | -6.45M | -8.07M | -9.06M |
| Cash & Short-term Investments | 19.8K | 844K | 184K | 116K | 72.8K | 41.2K | 628K | 949K | 80.5K | 49.7K |
| Total Debt | 555K | - | 1.40M | 1.94M | 3.39M | 4.45M | 6.68M | 255K | 255K | 255K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.31M | -1.43M | -916K | -427K | -1.23M | -836K | -1.38M | -1.15M | -775K | 62.9K |
| Capital Expenditure | 0.00 | 11.8K | 20.0K | 229K | 98.6K | 10.5K | 20.8K | 72.9K | 104K | 63.8K |
| Free Cash Flow | -1.31M | -1.44M | -936K | -656K | -1.33M | -847K | -1.40M | -1.22M | -879K | -824.00 |
| Ratios | ||||||||||
| ROA | -613.0% | -157.0% | -323.6% | -156.1% | -262.8% | -410.6% | -263.6% | -140.4% | -275.7% | -98.6% |
| Net Profit Margin | -4,934.4% | -1,060.6% | -138.2% | -77.1% | -175.6% | -201.3% | -357.2% | -221.6% | -169.1% | -76.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Quick-Med Technologies Inc dividends
Quick-Med Technologies Inc has not paid dividends in the last 10 fiscal years.
Who owns Quick-Med Technologies Inc
Ownership data of Quick-Med Technologies Inc is not available yet.
Quick-Med Technologies Inc company profile
- Company name
- Quick-Med Technologies Inc
- Ticker
- QMDT.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 5
- Fiscal year end
- June
- Address
- 902 NW 4th Street, Gainesville, FL, United States, 32601
- Phone
- 352-379-0611
- Website
- quickmedtech.com
About Quick-Med Technologies Inc
Quick-Med Technologies, Inc. focuses on sustainable antimicrobial technologies. It provides treatment optimization, laboratory prototyping to factory scale-up, domestic and international regulatory guidance, microbiological efficacy testing including viruses, patent expertise, technology evaluations, antimicrobials market evaluations, and scientific invention and original research products. The company's core technologies include Nimbus, a non-leaching antimicrobial wound dressing material; Stay Fresh, a sequestered hydrogen peroxide-based antimicrobial technology; and superabsorbent antimicrobial materials. In addition, it offers bioguard, DriGo-HP, antimicrobial care products, antimicrobial textiles, and antimicrobial paints and coatings products. Quick-Med Technologies, Inc. was incorporated in 1997 and is headquartered in Gainesville, Florida.
Quick-Med Technologies Inc management
2- Dr. Gregory S. Schultz Ph.D.Chairman & Scientific Advisor · born 1950
- Dr. Bernd Liesenfeld Ph.D.Principal Executive Officer, President & Director · born 1970